New and under explored epigenetic modulators in search of new paradigms

Area of Science:

• Epigenetics and Molecular Biology
• Medicinal Chemistry
• Drug Discovery

Background:

• Epigenetic pathway dysregulation is implicated in numerous diseases, including cancer, aging, and diabetes.
• Epigenetic aberrations are significantly more prevalent in cancers than genetic mutations.
• Current epigenetic modulators show promise but suffer from dose-limiting toxicities and suboptimal efficacy.

Purpose of the Study:

• To provide insights into novel and underexplored epigenetic modulators.
• To highlight the potential of these molecules as therapeutic agents.
• To discuss their utility as templates for new pharmacophores.

Main Methods:

• Literature review of recent advancements in epigenetic modulator synthesis and biological studies.
• Analysis of emerging epigenetic modulator classes.
• Exploration of structure-activity relationships and therapeutic potential.

Main Results:

• Identification of new classes of epigenetic modulators.
• Discussion of their unique chemical scaffolds and pharmacophore potential.
• Highlighting strategies to overcome limitations of existing therapies.

Conclusions:

• Novel epigenetic modulators represent a promising frontier in disease treatment.
• These molecules offer potential for improved therapeutic efficacy and safety profiles.
• Further research into their synthesis and biological activity is warranted for drug development.